The rapid expansion of peptide therapeutics manufacturing, the growing RNA therapeutics CDMO market, and rising demand for GMP peptide synthesis services are reshaping the pharmaceutical outsourcing landscape. These trends are fueling the growth of the Peptide and Oligonucleotide CDMO Market, as biotechnology and pharmaceutical companies increasingly rely on specialized contract development and manufacturing organizations (CDMOs) to accelerate drug development, reduce production costs, and ensure regulatory compliance.

The Peptide and Oligonucleotide CDMO Market was valued at USD 3.5 billion in 2024 and is projected to grow from USD 4.0 billion in 2025 to USD 14.2 billion by 2034, registering a robust CAGR of 15.1% during the forecast period (2025–2034).

Growing Demand for Peptide Therapeutics Manufacturing

Peptide therapeutics manufacturing has become a vital component of modern drug development as peptide-based medicines continue to gain popularity for treating chronic and complex diseases. Peptides offer high target specificity, strong biological activity, and favorable safety profiles, making them valuable for conditions such as diabetes, cancer, metabolic disorders, and infectious diseases.

Manufacturing peptide therapeutics requires sophisticated synthesis technologies, purification processes, and stringent quality control to ensure product consistency and regulatory compliance. Advances in solid-phase peptide synthesis (SPPS), liquid-phase synthesis, and hybrid manufacturing approaches have significantly improved production efficiency while reducing manufacturing costs.

Pharmaceutical companies increasingly partner with specialized CDMOs to access scalable production capabilities, advanced analytical testing, and regulatory expertise, allowing them to accelerate product commercialization while focusing on research and clinical development.

Expansion of the RNA Therapeutics CDMO Market

The RNA therapeutics CDMO market has experienced remarkable growth with the success of messenger RNA (mRNA), antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and other RNA-based therapies. These innovative treatments are transforming the management of genetic diseases, infectious diseases, oncology, and rare disorders.

Manufacturing RNA therapeutics requires highly specialized expertise in oligonucleotide synthesis, purification, formulation, and aseptic filling. CDMOs provide end-to-end services that support pharmaceutical companies throughout preclinical development, clinical trials, and commercial manufacturing.

Growing investments in RNA research, expanding clinical pipelines, and increasing regulatory approvals are driving demand for experienced CDMO partners capable of delivering high-quality, scalable manufacturing solutions. The growing interest in personalized medicine and gene-based therapies is expected to further accelerate this segment.

Importance of GMP Peptide Synthesis Services

GMP peptide synthesis services are essential for producing pharmaceutical-grade peptides that meet international regulatory standards for clinical and commercial use. Good Manufacturing Practice (GMP) compliance ensures consistent product quality, safety, traceability, and manufacturing reliability.

Modern GMP facilities utilize automated synthesis platforms, advanced purification technologies, and comprehensive analytical testing to manufacture peptides with high purity and reproducibility. These services include process development, scale-up manufacturing, quality assurance, and regulatory documentation.

As peptide therapeutics progress through clinical development toward commercialization, pharmaceutical companies increasingly rely on GMP-certified CDMOs to meet stringent regulatory requirements while ensuring uninterrupted supply chains.

The growing complexity of peptide molecules is also driving demand for innovative manufacturing technologies capable of producing high-purity compounds at commercial scale.

Peptide and Oligonucleotide CDMO Market Overview

The Peptide and Oligonucleotide CDMO Market is experiencing significant growth due to increasing outsourcing by pharmaceutical and biotechnology companies, rising investment in RNA therapeutics, and expanding demand for precision medicines. According to Polaris Market Research, the market continues to benefit from advances in synthetic chemistry, bioprocessing technologies, and regulatory expertise that enable efficient development and large-scale manufacturing of complex therapeutics.

The market is also supported by the growing number of peptide and oligonucleotide drug candidates entering clinical trials, creating sustained demand for specialized contract manufacturing services.

Market Segmentation

The Peptide and Oligonucleotide CDMO Market can be segmented based on product type, service type, application, and end user.

By Product Type

• Peptide therapeutics
• Oligonucleotide therapeutics
• RNA therapeutics
• DNA therapeutics

Peptide therapeutics account for a substantial market share due to their expanding use across multiple therapeutic areas.

By Service Type

• Process development
• GMP peptide synthesis services
• Analytical testing
• Scale-up manufacturing
• Commercial manufacturing
• Fill-finish services

Commercial manufacturing and GMP synthesis services represent major revenue-generating segments because of increasing regulatory requirements and commercialization activities.

By Application

• Oncology
• Metabolic disorders
• Cardiovascular diseases
• Rare genetic disorders
• Infectious diseases
• Neurological disorders

Oncology remains the leading application segment due to the growing pipeline of targeted peptide and RNA-based therapeutics.

By End User

• Pharmaceutical companies
• Biotechnology companies
• Academic and research institutes

Pharmaceutical and biotechnology companies dominate the market as they increasingly outsource complex manufacturing operations to specialized CDMOs.

Discover the Complete Report Here:

https://www.polarismarketresearch.com/industry-analysis/peptide-and-oligonucleotide-cdmo-market

Some of the major players operating in the global peptide and oligonucleotide CDMO market include:

• Aurigene Pharmaceutical Services Ltd.
• Bachem Group
• CordenPharma
• Creative Peptides
• Curia Global, Inc.
• EUROAPI
• Genscript Biotech Corporation
• Lonza Group
• Merck KGaA
• PolyPeptide Group
• Senn Chemicals AG
• STA Pharmaceutical Co. Ltd.
• Sylentis, S.A.
• Thermo Fisher Scientific Inc.
• Wuxi AppTec

Regional Analysis

North America leads the Peptide and Oligonucleotide CDMO Market due to a well-established biopharmaceutical industry, strong investment in biotechnology research, advanced manufacturing infrastructure, and the presence of leading CDMO providers.

Europe holds a significant market share supported by expanding pharmaceutical research, favorable regulatory frameworks, and increasing adoption of peptide- and oligonucleotide-based therapeutics.

Asia Pacific is projected to witness the fastest growth during the forecast period owing to rapidly expanding pharmaceutical manufacturing capabilities, competitive production costs, skilled workforce availability, and growing biotechnology investments in countries such as China, India, South Korea, and Japan.

Latin America and the Middle East & Africa are gradually strengthening their contract manufacturing capabilities as healthcare investments increase and regional pharmaceutical industries continue to develop.

Future Outlook

The future of the Peptide and Oligonucleotide CDMO Market will be driven by continued advancements in peptide therapeutics manufacturing, rapid expansion of the RNA therapeutics CDMO market, and increasing demand for GMP peptide synthesis services. The growing adoption of precision medicine, gene-based therapies, and personalized treatment approaches will continue to expand the pipeline of peptide and oligonucleotide drugs requiring specialized manufacturing support.

As pharmaceutical companies increasingly outsource complex production processes to experienced CDMOs, investments in automation, continuous manufacturing, advanced analytical technologies, and regulatory compliance will become even more important. These innovations are expected to improve manufacturing efficiency, reduce time to market, and support the long-term growth of the global peptide and oligonucleotide contract development and manufacturing industry.

More Trending Latest Reports By Polaris Market Research:

Virtual Clinical Trials Market

Oxycodone Drugs Market

Bioinformatics Services Market

Healthcare Business Banking Solutions and Services Market

Cbd Nutraceuticals Market

Vascular Imaging Market

Surgical Helmet Market

teleneurology market